期刊文献+

结直肠神经内分泌肿瘤WHO分级和预后的关系 被引量:11

Clinieopathological features of colorectal neuroendoerine neoplasms and prognostic significance of WHO staging system
原文传递
导出
摘要 目的探讨结直肠神经内分泌肿瘤的临床病理特征及其与2010年版WHO消化系统肿瘤分类胃肠胰神经内分泌肿瘤命名和分级的关系。方法复习73例结直肠神经内分泌肿瘤的临床病理资料,重新阅读所有病例的存档切片,免疫组织化学染色采用EnVision法,53例有随访结果。结果本组病例中男41例,女32例,中位年龄53岁(19—79岁),65例肿瘤位于距肛门10cm以内的直肠,45例肿瘤≤1cm,无转移病例。11例肿瘤最大径1~2cm,其中有2例转移。17例肿瘤最大径〉2cm,其中12例转移,转移率与肿瘤大小密切相关(P=0.000)。免疫组织化学标记证实所有病例均有神经内分泌标志物表达[突触素和(或)嗜铬粒素A阳性],按照2010年WHO消化系统肿瘤分类关于神经内分泌肿瘤的命名和分类标准,本组中神经内分泌瘤(NET)65例,其中1级(NET,G1)51例,2级(NET,G2)14例,神经内分泌癌(NEC,G3)4例,混合性腺神经内分泌癌(MANEC)4例。随访资料显示,G1获随访的34例无肿瘤相关死亡病例,2例分别转移至盆腔和肝脏,其余均无复发转移(6~179个月);G2获随访的12例中有5例转移,其中2例肿瘤相关性死亡,存活9例(17—118个月);4例G3均转移,其中3例肿瘤相关性死亡;混合性腺神经内分泌癌4例,有2例肿瘤相关死亡。本组肿瘤各级别之间转移率和病死率及总生存率的差异均有统计学意义(P=0.000)。结论结直肠神经内分泌肿瘤是一组预后差异显著的肿瘤,大多数显示惰性的生物学行为,2010年版WHO消化系统肿瘤分类神经内分泌肿瘤命名和分级与此类肿瘤的临床生物学行为之间有较好的对应关系。 Objective To investigate the clinicopathological characteristics of colorectal neuroendocrine neoplasms (NENs) and the prognostic significance of the new WHO classification and staging system about gastroenteropancreatic NENs. Methods The clinical and pathological records were reviewed in 73 patients with colorectal NENs (carcinoids). All slides were retrieved and reviewed, immunohistoehemical staining (EnVision method ) was perfomed and follow-up information retrieved. Results Forty-one men and thirty-two women were included with a median age of 53 years (19-79 years). The location of the primary tumors in 65 patients was within 10 cm fi'om the anorectal line. In 45 cases, the tumor diameter was ~〈 1 cm ( no metastasis occurred) ; in 11 cases, the tumor diameter was ;, 1 cm but ~〈2 cm ( two patients had metastatic tumors) ; in 17 cases, the tumor diameter was 〉 2 cm ( 12 patients had metastatic tumors). The metastatic rate was significantly correlated with tumor size (P = 0. 000). All tumors were immunoreactivity for synaptophysin and/or ehromogranin A. According to the criteria of WHO classification and staging system about gastroenteropancreatic NENs, there were 65 cases of neuroendocrine tumors, including 51 cases of grade 1 ( G1 ), 14 cases of grade 2 ( G2), 4 cases of neuroendocrine carcinoma(G3) and 4 cases of mixed adenoneuroendocrine carcinoma. Following-up data showed that of the 34 patients with G1 tumor, there were no tumor-related death, but two patients showed metastases, and the remaining patients were disease free for 6 to 179 months. Of the 12 patients with G2 tumors, five developed metastasis, there were two tumor-related deaths, and the nine surviving patients were alive for 17 to 118 months. Of the four G3 patients, all developed metastasis and there were three tumor-related deaths. Of the four mixed adenoneuroendocrine carcinoma there were two tumor-related deaths. The difference of metastatic rate, tumor-related mortality, and overall survival among different grading groups in this series was statistically significant (P = 0. 000). Conclusions Colorectal neuroendocrine neoplasm is a group of tumors with distinct prognostic difference, and most of these tumors show an indolent clinical behavior. There is a good correlation between the new WHO classification and staging system of gastroenteropancreatic NENs and their clinical behaviors.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2013年第3期191-196,共6页 Chinese Journal of Pathology
基金 国家自然科学基金(81070289)
关键词 结直肠肿瘤 神经内分泌瘤 预后 Colorectal neoplasms Neuroendocrine tumors Prognosis
  • 相关文献

参考文献19

  • 1中国胃肠胰神经内分泌肿瘤病理学诊断共识[J].中华病理学杂志,2011,40(4):257-262. 被引量:294
  • 2刘志,张新华,汪芳裕,周航波,章如松,周晓军.直肠类癌20例临床病理分析[J].临床与实验病理学杂志,2007,23(4):416-419. 被引量:20
  • 3Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of the neuroendocrine neoplasms of the digestive system// Bosman FT, Cameiro F, Hruban RH, et al. WHO classification of turnouts of the digestive system. Lyon: IARC Press, 2010 : 13.
  • 4Wang AY, Ahmad NA. Rectal carcinoids. Curr Opin Gastroenterol, 2006, 22 (5):529-535.
  • 5Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 2003, 97(4) :934-959.
  • 6张巧英,张新华,周航波,汪芳裕,马恒辉,陆珍凤,石群立,周晓军.消化道混合性腺-神经内分泌癌的临床病理分析[J].中华病理学杂志,2009,38(1):55-56. 被引量:19
  • 7Sasaki K, Murakami T, Kawasaki M, et al. The cell cycleassociated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol, 1987, 133(3) :579-584.
  • 8Volante M, Righi L, Berruti A, et al. The pathological diagnosis of neuroendocrine tumors : common questions and tentative answers. Virchows Arch, 2011,458(4) :393-402.
  • 9Goodell PP, Krasinskas AM, Davison JM, et al. Comparison of methods for proliferative index analysis for grading pancreatic well- differentiated neuroendocrine tumors. Am J Clin Pathol, 2012, 137(4) :576-582.
  • 10Hotta K, Shimoda T, Nakanishi Y, et al. Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int, 2006, 56(10) :591-596.

二级参考文献33

  • 1卢洪胜,张新华,周晓军.十二指肠混合性神经内分泌-腺管状癌1例[J].临床与实验病理学杂志,2005,21(5):638-638. 被引量:4
  • 2周航波,鲁波,马恒辉,周晓军.CD34与D2-40双重免疫组织化学染色技术在鉴别血管与淋巴管中的应用[J].中华病理学杂志,2007,36(5):342-343. 被引量:9
  • 3Solcia E, Capella C, Kleppel G, et al. World Health Organization classification of endocrine tumours. Pathology and genetics of endocrine tumours of the gastrointestinal tract. Lyon : IARC Press, 2000: 61.
  • 4Bakkelund K, Fossmark R, Nordrum I, et al. Signet ring cells in gastric carcinomas are derived from neuroendocrine cells. J Histochem Cytochem, 2006, 54(6):615-621.
  • 5Nugent SL, Cunningham SC, Alexiev BA, et al. Composite signet-ring cell/neuroendocrine carcinoma of the stomach with a metastatic neuroendocrine carcinoma component: a better prognosis entity. Diagn Pathol, 2007, 2:43.
  • 6Jiang SX, Mikami T, Umezawa A, et al.Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol, 2006, 30(8) :945-953.
  • 7Fujiyoshi Y, Kuhara H, Eimoto T. Composite glandular-endocrine cell carcinoma of the stomach. Report of two cases with goblet cell carcinoid component. Pathol Res Pract, 2005, 200 (11-12) : 823- 829.
  • 8Yaov JC,Hassan M,Phan A,et al.One hundred years after "carcinoid ":epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol,2008,26(18):3063-3072.
  • 9Yao JC,Shah MH,Ito T,et al.Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med,2011,364(6):514-523.
  • 10Raymond E,Dahan L,Raoul JL,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med,2011,36(6):501-513.

共引文献323

同被引文献70

引证文献11

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部